Posts Tagged :

Specialty Pharmacy Trends

Pharmacist-Driven Program for Evaluation of Pneumococcal Vaccination Among Adult Patients with Cystic Fibrosis 216 115 Shields Health Solutions

Pharmacist-Driven Program for Evaluation of Pneumococcal Vaccination Among Adult Patients with Cystic Fibrosis

This study highlights why engaging with a pharmacist during clinic visits facilitates appropriate immunization and supports adult patients with cystic fibrosis (PwCF).  

Evaluation of Pharmacist-Led Clinical Interventions for Mavacamten within an Integrated Health System Specialty Pharmacy Care Model 216 115 Shields Health Solutions

Evaluation of Pharmacist-Led Clinical Interventions for Mavacamten within an Integrated Health System Specialty Pharmacy Care Model

This study explores how a pharmacist-led mavacamten clinical management program ensures proactive management and identification of clinical and safety issues for patients on this complex therapy, as demonstrated by clinical…

Click, Prescribe, Deliver: The New Era of Direct-to-Consumer Pharmaceutical Care 70 70 Shields Health Solutions

Click, Prescribe, Deliver: The New Era of Direct-to-Consumer Pharmaceutical Care

As the healthcare landscape rapidly evolves, challenges related to medication access and affordability come to the forefront. Direct-to-consumer models reduce reliance on traditional intermediaries, such as in-person clinical visits, retail pharmacies, and…

Benchmarking the Future: Industry-Leading Specialty Pharmacy Outcomes 200 200 Shields Health Solutions

Benchmarking the Future: Industry-Leading Specialty Pharmacy Outcomes

Clinical outcomes in specialty pharmacy are more important than ever, yet many leaders still lack clear, comparable benchmarks to guide how they design, measure, and improve their programs.    Leveraging data from the largest health‑system…

2025 Specialty Pharmacy Outcomes Report 70 70 Shields Health Solutions

2025 Specialty Pharmacy Outcomes Report

Specialty pharmacy outcomes, elevated at scale. Download the Full 2025 Specialty Pharmacy Outcomes Report The 5th Annual Shields Specialty Pharmacy Outcomes Report is here. Featuring results from more than 2…

Unlock Your Specialty Pharmacy’s Hidden Value [INFOGRAPHIC] 200 200 Shields Health Solutions

Unlock Your Specialty Pharmacy’s Hidden Value [INFOGRAPHIC]

See how your health system can retain specialty volume, strengthen financial performance, and improve patient outcomes with the right strategy and support. Health systems without fully integrated specialty pharmacy models…

The Hidden Value of Integrated Specialty Pharmacy Partnership 1024 576 Shields Health Solutions

The Hidden Value of Integrated Specialty Pharmacy Partnership

Health systems build business cases for specialty pharmacy around predictable benefits: revenue retention, 340B optimization, and continuity of patient care. But the most significant impacts rarely appear in initial ROI…

Asembia Specialty Pharmacy Summit: Location, Dates, What to Expect, and What’s Happening 70 70 Shields Health Solutions

Asembia Specialty Pharmacy Summit: Location, Dates, What to Expect, and What’s Happening

Every year, more than 8,000 professionals and over 1,400 companies attend the leading specialty pharmacy conference in the nation, Asembia Summit 2025 marked its 21st anniversary — and we couldn’t be…

Revenue and Patient Volume Associated with Accreditation Restricted Limited Distribution Drugs in Health System Specialty Pharmacies 216 115 Shields Health Solutions

Revenue and Patient Volume Associated with Accreditation Restricted Limited Distribution Drugs in Health System Specialty Pharmacies

    Accreditation positions health system specialty pharmacies to expand access to high-value medications and supports integrated caremodels shown to reduce healthcare costs.  

Ambulatory Clinical Pharmacist Impact on Coverage Determinations for Specialty Oncology Medications 216 115 Shields Health Solutions

Ambulatory Clinical Pharmacist Impact on Coverage Determinations for Specialty Oncology Medications

    This poster evaluates the impact of an ambulatory clinical pharmacist (ACP) program on third party pharmacy coverage determinationoutcomes for specialty oncology medications prescribed from these clinics.